NCT06465303CompletedPhase 2
A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
An Exploratory, Randomised, Double-blind, Multicentre, Placebo-controlled Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
This is an exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026. The study population will consist of men and women with documented evidence of ST-elevation myocardial infarction (STEMI) referred to primary Percutaneous Coronary Intervention (PCI).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- First submitted
- 13 Jun 2024
- Start date
- 16 Jul 2024
- Primary completion date
- 2 Jul 2026
- Lead sponsor
- ResoTher Pharma
- Diseases
- Coronary artery disease
- NCT number
- NCT06465303
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 66
- From 16 Jul 2024 to the primary completion date, 2 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in any other study involving investigational drug(s) during the study and within 4 weeks prior to study entry
- Previous exposure to RTP-026
- Previous CABG
- Ongoing treatment with immune suppressive compounds
Other illness
- Evidence of active malignant disease
- Any condition that, in the view of the investigator, would suggest that the patient is unable to comply with the study protocol and procedures
Other
- Time from symptoms onset to primary PCI \> 12 hours
- Known contraindications to CMR
- ORBI Risk Score \> 12
Who the study is looking for
- Informed consent for participation in the study has been obtained prior to initiating any study-specific procedures
- Men between 18-85 years of age and post-menopausal women up to 85 years of age
- Acute onset of chest pain of \< 12 hours duration
- STEMI as characterized on ECG by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with a minimum of 1 mm concordant ST elevation or 1 mV ST elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior acute myocardial infarction (AMI)
- Eligible for primary PCI
- NLR in the range of 7-17 at hospital admission. In patients with chest pain lasting \> 3 - ≤ 6 hours at admission, the NLR should be in the range of 4.8-17 and for patients with chest pain lasting ≤ 3 hours at admission, the NLR should be in the range of 4.8-17, or the neutrophile count should be ≥ 9 x 10E9/L, irrespective of the lymphocyte count. For STEMI patients with an anterior or anterolateral infarction, the NLR should be ≥3.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hjertecenteret, Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.